A director at Aurora Cannabis Inc sold 13,390 shares at 9.300CAD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
AURORA CANNABIS - SELL | CAD20 vs. CAD13.2 (-11%) Improving cost structure but remains loss making Q3 revenues increased 15% sequentially Steep progress in cutting costs COVID-19 Comments. No further capital raises needed(?) Estimate revisions Entering the US with the Reliva acquisition Recap of the business transformation plan
The independent financial analyst theScreener just requalified the general evaluation of AURORA CANNABIS INCO. (CA), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date April 17, 2020, the closing price ...
Cannabis Q3 results could trigger further share price weakness Harmonizing valuations downward Concern no 1: Persistent losses at larger operators Concern no 2: Weak Q3 CY19 due to inventory build-up Concern no 3: Vaping health issues to impact US MSO and potentially delay Canadian introduction
We are initiating coverage of cannabis, an industry we forecast to grow by 9 times through 2030 amid widening legalization and increased participation for the Canadian, international, and U.S. markets. For Canada, despite recent recreational legalization, cannabis has penetrated just 12% of our estimated market, setting the stage for 20% CAGR through 2030. For the international market, we forecast market potential of nearly $43 billion and 23% CAGR through 2030 as more and more countries recog...
We are initiating coverage of cannabis, an industry we forecast to grow by 9 times through 2030 amid widening legalization and increased participation for the Canadian, international, and U.S. markets. For Canada, despite recent recreational legalization, cannabis has penetrated just 12% of our estimated market, setting the stage for 20% CAGR through 2030. For the international market, we forecast market potential of nearly $43 billion and 23% CAGR through 2030 as more and more countries recog...
We are initiating coverage of cannabis, an industry we forecast to grow by 9 times through 2030 amid widening legalization and increased participation for the Canadian, international, and U.S. markets. For Canada, despite recent recreational legalization, cannabis has penetrated just 12% of our estimated market, setting the stage for 20% CAGR through 2030. For the international market, we forecast market potential of nearly $43 billion and 23% CAGR through 2030 as more and more countries recogni...
We are initiating coverage of cannabis, an industry we forecast to grow by 9 times through 2030 amid widening legalization and increased participation for the Canadian, international, and U.S. markets. For Canada, despite recent recreational legalization, cannabis has penetrated just 12% of our estimated market, setting the stage for 20% CAGR through 2030. For the international market, we forecast market potential of nearly $43 billion and 23% CAGR through 2030 as more and more countries recogni...
Aurora cultivates and sells cannabis predominantly in Canada but also exports into the global medical market.Aurora has historically focused on medical cannabis but has benefited from the legalization of recreational cannabis in Canada in 2018. Recreational now accounts for roughly 50% of gross sales and has been rising, although this share is slightly lower than peers. We expect the medical market to shrink due to recreational legalization but forecast roughly 20% average annual growth for the ...
Aurora cultivates and sells cannabis predominantly in Canada but also exports into the global medical market.Aurora has historically focused on medical cannabis but has benefited from the legalization of recreational cannabis in Canada in 2018. Recreational now accounts for roughly 50% of gross sales and has been rising, although this share is slightly lower than peers. We expect the medical market to shrink due to recreational legalization but forecast roughly 20% average annual growth for the ...
Aurora is the main beneficiary of the growth in the global medicinal cannabis market. We estimate that market opportunity at USD114bn, which is significantly more than the USD8bn Canadian recreational market potential. The company is already one of the leaders in the European and the Latin American medicinal cannabis market, with for instance market share of around 45% in Germany and first and early mover advantage in other markets. Aurora is already in 22 international medical cannabis market...
With the upcoming Spinoff of its US cannabis investment arm, Aurora Cannabis, Inc. (ACB CN) continues to be front and center in the news as it strategically positions itself via acquisitions and partnerships for the upcoming legalization of recreational use of marijuana in Canada by October 17, 2018. This is why this company has quickly become the largest marijuana firm in Canada and one of the largest Globally. Distribution Details... For every 34 shares a Canadian resident investor holds in A...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.